HYQVIA IMMUNE GLOBULIN INFUSION (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE Trademark

Trademark Overview

On Friday, November 4, 2011, a trademark application was filed for HYQVIA IMMUNE GLOBULIN INFUSION (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE with the United States Patent and Trademark Office. The USPTO has given the HYQVIA IMMUNE GLOBULIN INFUSION (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE trademark a serial number of 85464358. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 15, 2014. This trademark is owned by Baxter International Inc.. The HYQVIA IMMUNE GLOBULIN INFUSION (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, all containing immune globulin infusion (human) and recombinant human hyaluronidase
hyqvia immune globulin infusion (human) with recombinant human hyaluronidase

General Information

Serial Number85464358
Word MarkHYQVIA IMMUNE GLOBULIN INFUSION (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE
Filing DateFriday, November 4, 2011
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 15, 2014
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, March 13, 2012

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Disclaimer with Predetermined Text"IMMUNE GLOBULIN INFUSION (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE"
Description of MarkThe mark consists of the stylized wording "HYQVIA IMMUNE GLOBULIN INFUSION (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE". Cascading dots appear from the "Y" in "HYQVIA" and arch over the "Q" in "HYQVIA".
Goods and ServicesPharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, all containing immune globulin infusion (human) and recombinant human hyaluronidase

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 8, 2011
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBaxter International Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDeerfield, IL 60015
Party NameBaxter International Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDeerfield, IL 60015

Trademark Events

Event DateEvent Description
Monday, December 15, 2014ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, December 15, 2014ABANDONMENT - NO USE STATEMENT FILED
Friday, May 16, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 15, 2014EXTENSION 4 GRANTED
Monday, May 5, 2014EXTENSION 4 FILED
Monday, May 5, 2014TEAS EXTENSION RECEIVED
Monday, May 5, 2014TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 24, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 23, 2013EXTENSION 3 GRANTED
Wednesday, September 18, 2013EXTENSION 3 FILED
Wednesday, September 18, 2013TEAS EXTENSION RECEIVED
Friday, April 26, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 25, 2013EXTENSION 2 GRANTED
Wednesday, April 3, 2013EXTENSION 2 FILED
Thursday, April 25, 2013CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, April 3, 2013TEAS EXTENSION RECEIVED
Saturday, November 10, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 9, 2012EXTENSION 1 GRANTED
Wednesday, November 7, 2012EXTENSION 1 FILED
Friday, November 9, 2012CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, November 7, 2012TEAS EXTENSION RECEIVED
Tuesday, May 8, 2012NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 13, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 13, 2012PUBLISHED FOR OPPOSITION
Wednesday, February 22, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sunday, February 5, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, January 30, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 30, 2012EXAMINER'S AMENDMENT ENTERED
Monday, January 30, 2012NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, January 30, 2012EXAMINERS AMENDMENT E-MAILED
Monday, January 30, 2012EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 25, 2012ASSIGNED TO EXAMINER
Wednesday, January 25, 2012PREVIOUS ALLOWANCE COUNT WITHDRAWN
Tuesday, January 24, 2012WITHDRAWN FROM PUB - OG REVIEW QUERY
Friday, January 6, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, January 6, 2012ASSIGNED TO LIE
Friday, December 16, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 16, 2011EXAMINER'S AMENDMENT ENTERED
Friday, December 16, 2011NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, December 16, 2011EXAMINERS AMENDMENT E-MAILED
Friday, December 16, 2011EXAMINERS AMENDMENT -WRITTEN
Wednesday, December 7, 2011ASSIGNED TO EXAMINER
Wednesday, November 9, 2011NOTICE OF DESIGN SEARCH CODE MAILED
Tuesday, November 8, 2011NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, November 8, 2011NEW APPLICATION ENTERED IN TRAM

Related Keywords

human recombinant hyaluronidase infusion immune globulin hyqvia gastrointestinal system psychiatric dermatological related hormonal disorders